ArticleKidney international reports2025
Risk of End-Stage Kidney Disease and Topiramate Use.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Topiramate and Kidney Protection: A Serendipitous Connection?Kidney international reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Topiramate is widely used for migraine prevention but has pleiotropic effects on renal sodium reabsorption and inflammation. Whether these effects could be associated with lower risk of end-stage kidney disease (ESKD) and cardiovascular outcomes is unknown. Methods: Among 1,745,580 patients with a diagnosis of migraine, the risk of ESKD, cardiovascular outcomes, and death was assessed after propensity matching in patients treated with topiramate versus untreated patients. Results: Overall, 317,936 patients treated with topiramate were properly matched with 317,936 controls by age (43 years old), sex (women: 86%), clinical and biological parameters, comorbid conditions, and baseline medications. After a median follow-up of 3.5 years, patients receiving topiramate had a significant lower risk of ESKD (hazard ratio [HR]: 0.850; 95% confidence interval [CI]: 0.776-0.930; Conclusion: In men and women with migraine, topiramate was significantly associated with lower risks of ESKD and death, but higher risks of ischemic stroke or thromboembolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.